NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00367185,Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma,https://clinicaltrials.gov/study/NCT00367185,,COMPLETED,"In multiple myeloma, combination chemotherapy with melphalan plus prednisone has been used since the 1960s and is regarded as the standard of care in elderly patients. We assess whether the addition of thalidomide to this combination or adapted high-dose chemotherapy, using a melphalan 100 mg/m2 -based regimen, would improve survival.",NO,Multiple Myeloma,DRUG: Thalidomide,Overall survival,Best response rate|Progression-free survival|Survival after progression|Toxicity,,"University Hospital, Lille",,ALL,OLDER_ADULT,PHASE3,500,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,IFM 99-06,2000-05,,2005-10,2006-08-22,,2006-08-22,"Lille University Hospital, Lille, 59037, France",
